The European Medicines Agency has recommended that 10 new treatments be awarded pan-EU marketing authorization, including Libmeldy (OTL-200), Orchard Therapeutics’ gene therapy for treating metachromatic leukodystrophy (MLD), and Leqvio (inclisiran), Novartis’s potential blockbuster cholesterol lowering drug.
If approved by the European Commission, Libmeldy will be the first commercial therapy and first gene therapy for eligible patients...